Patent EP0350151A2 successfully refreshed from Google Patents.
EP0350151A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Diagnosing and treating chronic fatigue syndrome
Assignee: HEM Pharmaceuticals Corp
•
Filing: 1989-04-26
•
Granted: —
•
Expires: 2009-04-26
Abstract
Abstract Chronic Fatigue Syndrome is diagnosed and distinguished from other conditions presenting a similar clinical appearance by assessing the 2′-5′A oligonucleotide levels in the patient's circulating peripheral leucocytes and comparing the result obtained to that of healthy individuals. Double-stranded RNAs, notably mismatched dsRNAs, when administered in appropriate amounts, increase the 2′-5′A in patients with Chronic Fatigue Syndrome to normal levels and improve the clinical symptoms.
Inventors
- 👤 William A. Carter
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 14:06
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61P; A61P25/00; A61P25/28; C; C07; C07H; C07H21/00; C12; C12Q; C12Q1/00; C12Q1/68; C12Q1/6876; C12Q1/6883
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
57 words
A method of diagnosing chronic fatigue syndrome in a human patient comprising assessing the level of intracellular 2′-5′A oligonucleotides in a sample of the patient's peripheral blood and comparing same to predetermined levels of 2′-5′A oligonucleotides in healthy individuals, reduced 2′-5′A oligonucleotide levels as compared with those in healthy individuals indicating the presence of chronic fatigue syndrome.
Claim 2
Independent Claim
57 words
A method of diagnosing chronic fatigue syndrome in a human patient comprising assessing the level of intracellular 2′-5′A oligonucleotides in a sample of the patient's peripheral blood and comparing same to predetermined levels of 2′-5′A oligonucleotides in healthy individuals, reduced 2′-5′A oligonucleotide levels as compared with those in healthy individuals indicating the presence of chronic fatigue syndrome.
Claim 3
Independent Claim
47 words
A method of distinguishing viral-induced chronic fatigue syndrome from primary psychological or neuropsychiatric disorders resembling same in a person comprising assessing the level of intracellular 2′-5′A oligonucleotides in a sample of the patient's peripheral blood and comparing same to predetermined levels of 2′-5′ oligonucleotides in healthy individuals.
Claim 4
Independent Claim
47 words
A method of distinguishing viral-induced chronic fatigue syndrome from primary psychological or neuropsychiatric disorders resembling same in a person comprising assessing the level of intracellular 2′-5′A oligonucleotides in a sample of the patient's peripheral blood and comparing same to predetermined levels of 2′-5′ oligonucleotides in healthy individuals.
Claim 5
Dependent Claim
16 words
The method of claim 1 or claim 2 in which the 2′-5′A oligonucleotide is 2′-5′ oligoadenylate.
Claim 6
Dependent Claim
39 words
The method of claim 1 or claim 2 in which the diagnosis is presumptively positive for chronic fatigue syndrome when the 2′-4′ oligonucleotide in the patient sample is less than 0.2 nanomoles of 2′-5′A per gram of lymphocyte protein.
Claim 7
Dependent Claim
17 words
Use of a mismatched dRNA for the manufacture of a medicament for treating viral-induced chronic fatigue syndrome.
Claim 8
Dependent Claim
17 words
Use of a mismatched dRNA for the manufacture of a medicament for treating viral-induced chronic fatigue syndrome.
Claim 9
Dependent Claim
16 words
Use of claim 5 in which the mismatched dsRNA is polyadenylic acid complexed with polyuridylic acid.
Claim 10
Dependent Claim
31 words
Use of claim 5 in which the mismatched dsRNA is a complex of a polyinosinate and a polycytidylate containing from 1 in 5 to 1 in 30 uracil or guanidine bases.
Claim 11
Dependent Claim
36 words
Use of claim 7 in which the mismatched dsRNA is rI n ·r(C₁₁₋₁₄,U) n or the mismatched dsRNA contains regions of bond breakage and exhibits the favorable therapeutic ratio property of rI n ·r(C₁₁₋₁₄,U) n .
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.